LONDON, April 6, 2017 /PRNewswire/ -- About Muscle Relaxant Drugs
Muscle spasticity is caused by damage to the spinal cord or brain. Nerves in the brain and spinal cord help relax the muscles during the idle state. Conditions that affect the brain or spinal cord such as multiple sclerosis, cerebral palsy, and stroke can interfere with normal muscle relaxation, leading to involuntary muscle spasms. This will impair the ability to walk, work, sleep, or just function normally. The muscles can also become excessively tense and develop overactive or overresponsive reflexes. Severe cases can lead to deep disability, including an inability to straighten out joints. Download the full report: https://www.reportbuyer.com/product/4796564/Technavio's analysts forecast the global muscle relaxant drugs market to grow at a CAGR of 5.64% during the period 2017-2021. Covered in this report
The report covers the present scenario and the growth prospects of the global muscle relaxant drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The market is divided into the following segments based on geography:
- Americas - APAC - EMEA Technavio's report, Global Muscle Relaxant Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors
- Pfizer - Ipsen Group - Allergan - Novartis - Teva Pharmaceuticals Other prominent vendors
- Acorda Therapeutics - Aldeyra Therapeutics - Canbex Therapeutics - Daewoong - Emcure Pharmaceuticals - Endo International - Fresenius Kabi - Galderma - INSYS Therapeutics - Johnson & Johnson - Lannett Company - Merz Pharma - Mylan - Par Pharmaceutical - PhytoTech Therapeutics - Revance Therapeutics - Sun Pharmaceutical Industries - Takeda Pharmaceutical Market driver
- Presence of a large patient pool driving adoption rates. - For a full, detailed list, view our report Market challenge
- Side effects associated with use of muscle relaxants hamper adoption rates. - For a full, detailed list, view our report Market trend
- Advanced drug delivery technologies fuels adoption of muscle relaxants. - For a full, detailed list, view our report Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report. Methodology
Download the full report: https://www.reportbuyer.com/product/4796564/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-muscle-relaxant-drugs-market-2017-2021-300436170.html
SOURCE ReportBuyer
